Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.

Ward, Rachael; Huang, Zhen; Rockhold, Frank W; Baumgartner, Iris; Berger, Jeffrey S; Blomster, Juuso I; Fowkes, F Gerry R; Katona, Brian G; Mahaffey, Kenneth W; Norgren, Lars; Vemulapalli, Sreekanth; Povsic, Thomas J; Mehta, Rajendra; Hiatt, William R; Patel, Manesh R; Jones, W Schuyler (2020). Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American Heart Journal, 220, pp. 51-58. Elsevier 10.1016/j.ahj.2019.11.007

Text 1-s2.0-S0002870319303084-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (327kB)

BACKGROUND

Rates and predictors of major bleeding in patients with peripheral artery disease (PAD) treated with antiplatelets have not been well studied. This post hoc analysis of EUCLID aimed to determine the incidence of major/minor bleeding, predictors of major bleeding, and risk of major adverse cardiovascular events (MACE) following major bleeding events.

METHODS

EUCLID, a multicenter randomized controlled trial of 13,885 patients with symptomatic PAD, compared ticagrelor with clopidogrel for the prevention of MACE. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. Baseline characteristics were used to develop a multivariable model to determine factors associated with TIMI major bleeding. The occurrence and timing of MACE relative to a first major bleeding event were determined.

RESULTS

TIMI major bleeding occurred in 2.3% of participants overall (0.94 event/100 patient-years). There was no significant difference in major bleeding rates by treatment assignment. Factors associated with TIMI major bleeding included older age, geographic region, Rutherford class, and β-blocker use. Patients with TIMI major bleeding postrandomization had an increased risk of MACE (hazard ratio [HR] 4.46; 95% CI 3.40-5.84; P < .0001) compared with those without major bleeding; the association was strongest within 30 days after a bleeding event.

CONCLUSIONS

In patients with symptomatic PAD, 0.94 major bleeding event/100 patient-years was observed and associated with older age, residing in North America, disease severity, and β-blocker use. Patients who had a major bleeding event were significantly more likely to experience MACE, especially within the first 30 days, when compared with patients who did not have major bleeding.

Interest & Impact

Downloads

1 since deposited on 24 Jan 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item